Clinical Trial Update: A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) [Phase 3]

View source ↗

Summary

Phase 3 clinical study comparing Golcadomide plus Rituximab versus Investigator's Choice in relapsed/refractory follicular lymphoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Golcadomide (golcadomide)
• Rituximab (rituximab)

Snippet

Sponsor: Celgene | Conditions: Follicular Lymphoma | Phase 3 | Status: RECRUITING